MicroStockProfit.com releases investment report featuring Encorium Group

Apr 16 2010

MicroStockProfit.com announces an investment report featuring Encorium Group Inc. (Nasdaq:ENCO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ENCO

Encorium Group Inc. (ENCO) is a clinical research organization (CRO), which is engaged in the design and management of clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company's clients consist of companies in the pharmaceutical, biotechnology and medical device industries. The Company offers a range of clinical research and development services supporting phase I through phase IV clinical trials, such as strategic trial planning, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, quality assurance, outsourcing of clinical staff and medical device certification in the European Union. The Company's services include study protocol design, clinical trials management, global data management services, biostatistics, medical and regulatory affairs, quality assurance and compliance, and medical report writing. 

In the report, the analyst notes:

"ENCO recently announced that it will file a Form 12b-25 with the Securities and Exchange Commission, which will provide the Company with a 15-calendar day extension for filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The Company's independent registered accounting firm has not completed its audit of the Company's financial statements and has not provided its report and consent for the Company's Annual Report.  The Company will file its Form 10-K as soon as its independent registered accounting firm provides its report on those financial statements and its consent."